J Reynes

Summary

Country: France

Publications

  1. pmc Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status
    David Morquin
    Medical Intensive Care Unit, Gui de Chauliac Teaching Hospital, University of Montpellier 1, Montpellier, France
    Ann Intensive Care 2:25. 2012
  2. doi request reprint Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2
    Jacques Reynes
    Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France
    AIDS 27:1295-302. 2013
  3. pmc Suppression of HIV-1 replication by microRNA effectors
    Christine Chable-Bessia
    Institut de Génétique Humaine CNRS UPR1142, Laboratoire de Virologie Moleculaire, Montpellier, France
    Retrovirology 6:26. 2009
  4. pmc Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients
    Gael Petitjean
    Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
    Retrovirology 4:60. 2007
  5. ncbi request reprint TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
  6. ncbi request reprint [Antiretroviral therapies: strategic perspectives for the future]
    J Reynes
    Service des Maladies Infectieuses et Tropicales, UMR145 VIH er maladies associdées, CHU de Montpellier, France
    Med Trop (Mars) 67:367. 2007
  7. pmc Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy
    M Segondy
    Department of Virology and Department of Infectious and Tropical Diseases, Montpellier University Hospital, Montpellier, France
    J Clin Microbiol 36:3392-5. 1998
  8. doi request reprint Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
  9. doi request reprint Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)
    Sebastien Gallien
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 66:184-91. 2011
  10. ncbi request reprint Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy
    M N Rousseau
    Laboratory of Virology and Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire (CHU, Montpellier, France
    J Acquir Immune Defic Syndr 26:36-43. 2001

Detail Information

Publications82

  1. pmc Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status
    David Morquin
    Medical Intensive Care Unit, Gui de Chauliac Teaching Hospital, University of Montpellier 1, Montpellier, France
    Ann Intensive Care 2:25. 2012
    ..abstract:..
  2. doi request reprint Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2
    Jacques Reynes
    Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France
    AIDS 27:1295-302. 2013
    ..To assess the frequency of glomerular and tubular proteinuria in a cohort of HIV-infected patients, and to determine the factors associated with each type of injury...
  3. pmc Suppression of HIV-1 replication by microRNA effectors
    Christine Chable-Bessia
    Institut de Génétique Humaine CNRS UPR1142, Laboratoire de Virologie Moleculaire, Montpellier, France
    Retrovirology 6:26. 2009
    ..Interestingly, knockdown of RCK/p54 or DGCR8 resulted in virus reactivation in PBMCs isolated from HIV infected patients treated with suppressive HAART...
  4. pmc Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients
    Gael Petitjean
    Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
    Retrovirology 4:60. 2007
    ..The presence of HIV-1 preintegration reservoir was assessed in an in vitro experimental model of latent HIV-1 infection, and in patients treated or not with highly active antiretroviral therapy (HAART)...
  5. ncbi request reprint TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
    ..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
  6. ncbi request reprint [Antiretroviral therapies: strategic perspectives for the future]
    J Reynes
    Service des Maladies Infectieuses et Tropicales, UMR145 VIH er maladies associdées, CHU de Montpellier, France
    Med Trop (Mars) 67:367. 2007
  7. pmc Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy
    M Segondy
    Department of Virology and Department of Infectious and Tropical Diseases, Montpellier University Hospital, Montpellier, France
    J Clin Microbiol 36:3392-5. 1998
    ....
  8. doi request reprint Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  9. doi request reprint Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)
    Sebastien Gallien
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 66:184-91. 2011
    ..once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine...
  10. ncbi request reprint Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy
    M N Rousseau
    Laboratory of Virology and Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire (CHU, Montpellier, France
    J Acquir Immune Defic Syndr 26:36-43. 2001
    ..In these patients, genotypic resistance tests confirm the lack of alternative salvage therapy strategies based on the currently available antiretroviral drugs...
  11. ncbi request reprint Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection
    Pierre Portales
    Laboratoire d Immunologie, Hopital Saint Eloi, Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier, France
    AIDS 17:505-11. 2003
    ..As CTL play a major role in immune defence against HIV, we wanted to further characterize CTL activity and the effect of IFNalpha on it...
  12. doi request reprint Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis
    K C Psomas
    Departement des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier Cedex, France
    Med Mal Infect 42:15-9. 2012
    ..An increase of syphilis cases has been recorded in the past few decades, especially among HIV-infected patients. These patients often present with concomitant primary and secondary lesions or extensive presentations of syphilis...
  13. doi request reprint 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients
    N Bourgeois
    Laboratory of Parasitology Mycology, University Hospital, Nimes, University Montpellier I, Montpellier, Nimes, France
    HIV Med 11:670-3. 2010
    ..The aim of the study was to describe a new evolutionary form of visceral leishmaniasis observed in immunocompromised patients...
  14. pmc Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1
    K Triques
    Laboratoire Retrovirus, ORSTOM, Montpellier, France
    J Clin Microbiol 37:110-6. 1999
    ..5, yielded accurate measurement of the HIV load for all HIV-1 subtypes tested, which should allow the test to be used to assess disease prognosis and response to antiretroviral treatment in patients infected with a group M HIV-1 subtype...
  15. ncbi request reprint Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines
    E Renard
    The Department of Endocrinology, Lapeyronie Hospital, Montpellier, France
    Clin Endocrinol (Oxf) 51:223-30. 1999
    ..Alterations of body fat distribution have been recently reported in HIV-infected patients. We aimed to investigate whether the hormones modulating adipose tissue metabolism could be implicated...
  16. ncbi request reprint CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression
    J Reynes
    Service des Maladies Infectieuses et Tropicales, , Montpellier, France
    AIDS 15:1627-34. 2001
    ..Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density...
  17. doi request reprint Diagnostic approaches to imported schistosomal myeloradiculopathy in travelers
    A Makinson
    Department of Infectious Diseases, University Hospital, Montpellier, F 34295 Montpellier, France
    Neurology 71:66-7. 2008
  18. pmc Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conception
    V Le Moing
    Centre Hospitalier Universitaire, Montpellier, France
    HIV Med 9:897-900. 2008
    ..Whether pregnancy has an impact on the evolution of CD4 cell counts in women treated with highly potent antiretrovirals before conception remains largely unknown...
  19. ncbi request reprint Reasons for early abacavir discontinuation in HIV-infected patients
    Helene Peyriere
    Pharmacovigilance Center, Lapeyronie Hospital, Montpellier, France
    Ann Pharmacother 37:1392-7. 2003
    ..To determine incidence of and reasons for discontinuation of abacavir within the first 6 months of therapy...
  20. ncbi request reprint Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient
    Didier Bessis
    Service de Dermatologie Phlébologie, CHU Montpellier, Hopital Saint Eloi, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Eur J Dermatol 12:99-102. 2002
    ..We review the literature on previously reported cases of cutaneous necrosis following standard or pegylated IFN-alpha injection and discuss the different pathophysiological mechanisms that might be involved...
  21. ncbi request reprint Molecular diagnosis of culture-negative cerebral nocardiosis due to Nocardia abscessus
    Helene Marchandin
    Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Diagn Microbiol Infect Dis 55:237-40. 2006
    ..The patient is alive and well on imipenem and doxycycline therapy, 14 months after onset...
  22. doi request reprint Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients
    S Bertout
    Laboratoire de Parasitologie et Mycologie médicale UFR Pharmacie, UMI 233 UM 1 IRD UCAD UY1, Montpellier, France
    Clin Microbiol Infect 19:763-9. 2013
    ..Two genotypes may be responsible for a single episode of cryptococcosis. The possibility of mixed infection and diminished susceptibility to fluconazole or flucytosine must be considered for the management of cryptococcosis...
  23. doi request reprint [Adherence to antibiotherapy guidelines for acute community-acquired pneumonia in adults, in a teaching hospital]
    J S Martinez
    Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Med Mal Infect 40:468-75. 2010
    ..The authors had for aim to assess the conformity of antibiotic prescription with guidelines, for the management of community-acquired pneumonia, in a French University Hospital...
  24. ncbi request reprint Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia
    G J Thöni
    UPRES EA 2991, Sports, Performance, Health Laboratory, Faculty of Sport Sciences, Montpellier, France
    Diabetes Metab 28:397-404. 2002
    ..The management of abdominal fat accumulation and metabolic disorders in HIV1-infected patients, by an aerobic training program, is considered...
  25. doi request reprint Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake
    C Eiden
    Department of Medical Pharmacology and Toxicology, University Hospital of Montpellier, Montpellier, France
    Eur J Clin Microbiol Infect Dis 31:161-7. 2012
    ..PCZ therapeutic drug monitoring (TDM) is essential in order to early detect patients with low concentrations, to assess the etiology of such results, and to decide on the treatment strategy to apply...
  26. doi request reprint The fusion inhibitor enfuvirtide in recent antiretroviral strategies
    Alain Makinson
    Infectious Diseases Department, Montpellier University Hospital, CHU Montpellier, France
    Curr Opin HIV AIDS 4:150-8. 2009
    ..The purpose of this review is to discuss recent pharmacological, virological, and clinical data that concern enfuvirtide usage in different antiretroviral combinations...
  27. pmc Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen
    E Tuaillon
    Universite de Montpellier 1, INSERM Unité 1058, Montpellier, France
    J Clin Microbiol 50:3096-8. 2012
    ..21 to 0.09) in 12 patients experiencing HIV-1 virologic failure due to suboptimal adherence to ARV (P = 0.17). We estimated that six of these 18 patients will attain HBsAg values below 10 IU/ml after 10 years of treatment...
  28. doi request reprint Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial
    Matthieu Lafaurie
    Department of Infectious Diseases, Saint Louis Hospital, University of Paris 7, INSERM U897, 1 avenue Claude Vellefaux 75010 Paris, France
    J Antimicrob Chemother 62:1122-9. 2008
    ..However, it is unclear whether patients tolerating long-term zidovudine-containing regimens will benefit from a switch to non-zidovudine-containing regimens...
  29. doi request reprint [Infectious adverse events related to misuse of high-dose buprenorphine: a retrospective study of 42 cases]
    D Grau
    Hopital Lapeyronie, Centre d Evaluation et d Information sur la Pharmacodependance, CHU de Montpellier, France
    Rev Med Interne 31:188-93. 2010
    ..Misuse of high-dose buprenorphine (HDB), mainly by injection, is responsible of frequent infectious adverse events...
  30. ncbi request reprint Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz
    P Lochet
    Department of Infectious Diseases, Gui de Chauliac Hospital, Montpellier, France
    HIV Med 4:62-6. 2003
    ....
  31. ncbi request reprint Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo
    Pierre Portales
    Laboratoire d Immunologie, Hopital Saint Eloi, the Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier, France
    AIDS 17:495-504. 2003
    ..The aim of the present study was to better understand this defect in order to be able to restore NK function in HIV infection...
  32. doi request reprint [Antifungal treatments of candidemia in non-neutropenic patients: evaluation of practice in intensive care units]
    P Massanet
    Service de réanimation médicale assistance respiratoire, Hopital Gui de Chauliac, CHU de Montpellier, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Med Mal Infect 40:644-9. 2010
    ..The authors had for objective to assess systemic antifungal treatment for candidemia in non-neutropenic patients, in intensive care units (ICU), and compare the results with French 2004 recommendations...
  33. ncbi request reprint HIV-1 reactivation in resting peripheral blood mononuclear cells of infected adults upon in vitro CD4 cross-linking by ligands of the CDR2-loop in extracellular domain 1
    L Briant
    Laboratoire Infections Retrovirales et Signalisation Cellulaire, CRBM CRNS UPR 1086, Institut de Biologie, Montpellier, France
    J Acquir Immune Defic Syndr 21:9-19. 1999
    ..Our results indicate that the signaling events initiated in PBMCs by oligomerization of CD4 at the D1/CDR2-loop can trigger HIV-1 upregulation in infected individuals...
  34. pmc Comparison of various sample preparation methods for PCR diagnosis of visceral leishmaniasis using peripheral blood
    L Lachaud
    , Centre Hospitalier Universitaire, , Montpellier, France
    J Clin Microbiol 39:613-7. 2001
    ....
  35. doi request reprint [Ocular bartonellosis in an HIV-HVC coinfected patient]
    C Merle De Boever
    Service Maladies Infectieuses et Tropicales, CHU de Montpellier, 80 avenue Augustin Flèche, Montpellier, France
    Med Mal Infect 38:504-6. 2008
    ..Nuclear magnetic resonance revealed a retrobulbar neuritis. Confirmation was given by blood tests positive for B. henselae and the exclusion of other causes of neuroretinitis with biological data. Doxycycline cured the disease rapidly...
  36. ncbi request reprint Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases
    Helene Peyriere
    Department of Medical Pharmacology, Lapeyronie Hospital, CHU Montpellier, France
    J Acquir Immune Defic Syndr 35:269-73. 2004
    ..In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction...
  37. ncbi request reprint Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease
    Alain Makinson
    Infectious Diseases Department, Gui de Chauliac Hospital, CHU Montpellier, France
    Eur J Haematol 78:358-60. 2007
    ..This unrecorded strategy is discussed...
  38. ncbi request reprint [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir]
    Pierre Lochet
    Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, CHU Montpellier, Montpellier, France
    Therapie 60:175-81. 2005
    ..The objectives of our study were to assess frequency, severity and outcome of renal abnormalities, as well as to determine the risk of developing hypophosphataemia in HIV-infected patients receiving tenofovir...
  39. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  40. ncbi request reprint Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
    Mike Youle
    Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Clin Trials 7:86-96. 2006
    ..g., ENF) for triple-class-experienced patients...
  41. ncbi request reprint The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 density
    Thierry Vincent
    J Acquir Immune Defic Syndr 43:377-8. 2006
  42. ncbi request reprint Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults
    Dirk Schurmann
    Charite Universitatsmedizin, Berlin, Germany
    AIDS 21:1293-9. 2007
    ..To determine antiviral activity, pharmacokinetic properties, and safety of vicriviroc, an orally available CCR5 antagonist, as monotherapy in HIV-infected patients...
  43. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  44. pmc Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
    ..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
  45. ncbi request reprint Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients
    Edouard Tuaillon
    Laboratoire de Virologie, Hopital Lapeyronie, Montpellier, France
    AIDS 21:2343-5. 2007
    ..A lower number of HBs-SC was found in HBsAg-vaccinated patients compared with vaccinated controls...
  46. ncbi request reprint The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling
    Yea Lih Lin
    Institut de Genetique Humaine, CNRS UPR1142, Montpellier, France
    AIDS 20:1369-77. 2006
    ....
  47. ncbi request reprint Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B
    Brigitte Montes
    Department of Virology, University Hospital of Montpellier, Montpellier, France
    J Acquir Immune Defic Syndr 35:329-36. 2004
    ..To compare the prevalence of mutations associated with resistance to antiretroviral drugs and their interpretation in patients infected with non-B HIV-1 variants versus HIV-1subtype B-infected patients with similar treatment regimens...
  48. ncbi request reprint T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists
    Thierry Vincent
    Institut de Genetique Humaine, CNRS UPR 1142, Montpellier, France
    J Acquir Immune Defic Syndr 38:305-9. 2005
    ..In conclusion, we failed to demonstrate any impact of interindividual variability in T-cell surface CCR5 density on HCV infection, which would have argued against the use of CCR5 antagonists in HIV/HCV-coinfected subjects...
  49. ncbi request reprint Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjects
    Pierre Portales
    Clin Nutr 23:1244-5. 2004
  50. pmc Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals
    Jean Michel Fondere
    Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
    J Virol 78:10536-42. 2004
    ..The ELISPOT approach to targeting the HIV-1-Ag-SCs could be a useful method for identifying latently HIV-1-infected CD4(+) T cells carrying replication-competent HIV-1 in patients responding to HAART...
  51. ncbi request reprint Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20
    Anne Genevieve Marcelin
    Pitie Salpetriere Hospital, Paris, France
    AIDS 18:1340-2. 2004
    ..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
  52. ncbi request reprint Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infection
    Jacques Reynes
    J Acquir Immune Defic Syndr 34:114-6. 2003
  53. ncbi request reprint Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy
    Jean Michel Fondere
    Virology Laboratory, Hospital Lapeyronie, INSERM U470, Bâtiment Crastes de Paulet, Hospital A Villeneuve, France
    AIDS 17:2323-30. 2003
    ..To examine whether polyclonal activation of circulating B cells, in a process that involves CD40-CD40 ligand and cytokine interactions, could induced HIV-1-specific memory B cells to synthesize HIV-1-specific antibodies...
  54. ncbi request reprint Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 18:217-26. 2004
    ..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
  55. ncbi request reprint Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide
    Sharon Walmsley
    University of Toronto, Toronto, Ontario, Canada
    J Infect Dis 188:1827-33. 2003
    ..Safety was unaffected by the presence of positive antibody at any time point or change in level of antibody. There was no evidence that enfuvirtide cross-reactive gp41 antibody affects the efficacy or safety of enfuvirtide...
  56. ncbi request reprint Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay
    Jean Michel Fondere
    Departement de Virologie Clinique, Hopital Lapeyronie, 371 Avenue du Doyen Giraud, 34295 Montpellier edex 5, France
    J Clin Virol 29:33-8. 2004
    ..These cells serve as a potential source of reactivation of viral replication and remain a major obstacle for the eradication of HIV-1...
  57. ncbi request reprint Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance
    Bernard Masquelier
    Département de Virologie et Immunologie, Hopital Pellegrin, Bordeaux, France
    J Clin Virol 33:75-8. 2005
    ..In HIV-infected patients on first-line antiretroviral therapy, the significance of intermittent viremia and their relationship with drug resistance remain unclear...
  58. ncbi request reprint [New antiretroviral treatment modalities]
    Jacques Reynes
    Service des Maladies Infectieuses et Tropicales, UMR 145 VIH et Maladies Associées Hôpital Gui de Chauliac, 34295 Montpellier
    Presse Med 34:1S23-30. 2005
    ..For non-responders, thorough virological-pharmacological assessment is necessary, together with access to new molecules and new drug classes...
  59. ncbi request reprint Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
    ..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
  60. ncbi request reprint Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Clin Pharmacol Ther 72:10-9. 2002
    ....
  61. ncbi request reprint Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 40:404-12. 2005
    ....
  62. pmc Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection
    Yea Lih Lin
    Institut de Genetique Humaine, Centre National de la Recherche Scientifique, Unité Propre de Recherche 1142, Laboratoire d Immunologie de l Hôpital Saint Eloi, France
    Proc Natl Acad Sci U S A 99:15590-5. 2002
    ..These data explain why CCR5 density influences HIV-1 disease progression and underline the therapeutic interest of lowering CCR5 expression...
  63. ncbi request reprint Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy
    Jacques Reynes
    JAMA 291:46. 2004
  64. ncbi request reprint Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    Adriano Lazzarin
    Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita Salute University, Milan, Italy
    N Engl J Med 348:2186-95. 2003
    ....
  65. ncbi request reprint Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy
    Anne Marie Fournier
    From the Département de Virologie Clinique, Hôpitaux Lapeyronie et Saint Eloi, 34295 Montpellier Cedex 5, France
    AIDS 16:1755-60. 2002
    ....
  66. ncbi request reprint CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains
    Yea Lih Lin
    Institut de Genetique Humaine, Montpellier, France
    J Acquir Immune Defic Syndr 39:530-6. 2005
    ..027). These data suggest that CXCR4 overexpression during the course of the disease in some patients could favor the emergence of X4 strains...
  67. pmc Nocardia veterana isolated from ascitic fluid of a patient with human immunodeficiency virus infection
    Sylvain Godreuil
    Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, F 34295 Montpellier cedex 5, France
    J Clin Microbiol 41:2768-73. 2003
    ..A phylogenetic analysis was conducted and showed that N. veterana was most closely related to the recently characterized species Nocardia africana rather than to Nocardia vaccinii, as previously reported...
  68. ncbi request reprint Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population
    Marianne Saves
    INSERM U593 ex U330, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Clin Infect Dis 37:292-8. 2003
    ....
  69. ncbi request reprint Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
    Stephanie Badiou
    Department of Biochemistry, University Hospital, F34295 Montpellier, France
    J Infect 52:335-8. 2006
    ..The aim of our study was to explore the effect of tenofovir on phosphatemia and on tubular phosphate reabsorption...
  70. ncbi request reprint Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen
    Stephanie Badiou
    Department of Biochemistry, University Hospital, Montpellier 34295, France
    AIDS 17:772-4. 2003
  71. ncbi request reprint Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients
    Jean Michel Fondere
    Laboratoire de Virologie, Hopital Lapeyronie, Montpellier, France
    J Acquir Immune Defic Syndr 35:114-9. 2004
    ..We found that in AIDS patients, HIV-1-specific resting memory B cells circulate in the blood and can be quantified by their anti-HIV-1 antibody secretion after strong B cell polyclonal stimulation...
  72. ncbi request reprint Fulminant varicella hepatitis in a human immunodeficiency virus infected patient: case report and review of the literature
    Catherine Lechiche
    Infectious and Tropical Diseases Unit, Centre Hospitalier Gui de Chauliac, Montpellier, France
    Scand J Infect Dis 38:929-31. 2006
    ..Varicella zoster virus is an uncommon cause of acute liver disease which occurs mainly in immunocompromised patients. Acyclovir is the cornerstone of the treatment...
  73. ncbi request reprint Fat microinfiltration autografting for facial restructuring in HIV patients
    Sophie Domergue
    Department of Maxillo Facial and Oral Surgery, Head Prof Dr P Goudot, University Hospital of Montpellier, France
    J Craniomaxillofac Surg 34:484-8. 2006
    ..There are several options for surgical treatment of facial lipodystrophy, one of these was described by S. R. Coleman in 1994, the technique of fat transplantation...
  74. ncbi request reprint Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection
    Daniel J Skiest
    University of Texas Southwestern Medical Center, Dallas, Texas
    Clin Infect Dis 44:607-14. 2007
    ....
  75. pmc Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency
    Isaure du Chéné
    Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, UPR 1142, Montpellier, France
    EMBO J 26:424-35. 2007
    ..Finally, we show in different cellular models, including PBMCs from HIV-1-infected donors, that HIV-1 reactivation could be achieved after HP1gamma RNA interference...
  76. ncbi request reprint Suppression of microRNA-silencing pathway by HIV-1 during virus replication
    Robinson Triboulet
    Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, Montpellier, France
    Science 315:1579-82. 2007
    ..Our results highlight the involvement of the miRNA-silencing pathway in HIV-1 replication and latency...
  77. doi request reprint The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5
    Yea Lih Lin
    Institut de Genetique Humaine, CNRS UPR1142, France
    AIDS 22:430-2. 2008
    ..Among the chemokines that bind to CCR5, and induce its internalization, CCL5 is the most abundant in vivo. We show that the level of CCL5 production is a main factor determining CD4+ T cell surface CCR5 density...
  78. ncbi request reprint Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy
    Antoine Berry
    Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Centre Hospitalier Universitaire, 34295 Montpellier Cedex 5, France
    Scand J Infect Dis 36:225-7. 2004
    ..The report raises the question whether a rapid immune reconstitution may convert a latent visceral leishmaniasis into a symptomatic one...
  79. ncbi request reprint Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy
    Jean Marie Bard
    Faculte de Pharmacie, Laboratoire de Biochimie, Nantes, France
    Antivir Ther 11:361-70. 2006
    ....
  80. pmc Introduction of SARS in France, March-April, 2003
    Jean Claude Desenclos
    Département Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice, France
    Emerg Infect Dis 10:195-200. 2004
    ..Timely detection, isolation of probable case-patients, and quarantine of their contacts appear to have been effective in preventing the secondary spread of SARS in France...
  81. ncbi request reprint Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults
    Stephanie Badiou
    Laboratoire de Biochimie des Lipides, Department of Biochemistry, 371 Av du Doyen Gaston Giraud, Hopital Lapeyronie, CHU Montpellier F34295, France
    Atherosclerosis 172:273-9. 2004
    ..This study evaluates the effects of fenofibrate and/or Vitamin E on lipoprotein profile...
  82. ncbi request reprint Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells
    Anne Marie Fournier
    Departement de Virologie Clinique, Centre Hospitalier et Universitaire, Montpellier, France
    Clin Immunol 103:98-109. 2002
    ....